ClinicalTrials.gg
Enrolling by invitationNCT07180511Updated Sep 18, 2025

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

A Phase 3 interventional study of 10mg QY201 Placebo tablet and 20mg QY201 Placebo tablet in Atopic Dermatitis (AD), sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2025, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
34th of 190
460 · median 164
Started
2025
with 33 others
Phase 3
60 of 206
21 open now
Primary completion
2027-05
later than 46 of 81 live
Registered
161st of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 34th largest by planned enrollment of the 190 interventional ones that give a count, is one of 34 that started in 2025, is one of 60 in phase 3, reaches primary completion later than 46 of the 81 other live ones, and was the 161st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is able to communicate well with the investigator, fully understand the trial's purpose, nature, methods, and potential adverse reactions, voluntarily agrees to participate as a subject, understands and complies with all requirements of the study, and signs the ICF before any study procedures begin;
  2. At the time of signing the ICF, the subject is between 18 and 75 years of age (inclusive), regardless of gender;
  3. Has a history of AD for at least 1 year at screening and meets the Hanifin-Rajka diagnostic criteria (see Appendix 1) at screening;
  4. Meets the criteria for moderate-to-severe AD at both screening and baseline (all 4 criteria must be met):

    • vIGA-AD score ≥3 at screening and baseline (see Appendix 2);
    • EASI score ≥16 at screening and baseline (see Appendix 3);
    • BSA ≥10% at screening and baseline (see Appendix 4);
    • Weekly average of daily PP-NRS score ≥4 at baseline (see Appendix 6); [Note] The weekly average of the daily PP-NRS score at baseline will be calculated based on the scores recorded daily during the 7 consecutive days prior to baseline. If there are fewer than 7 days of daily PP-NRS scores during the 7 consecutive days prior to baseline, scores from at least 4 days must be used for the calculation. If there are fewer than 4 days, randomization should be postponed, but must not exceed the maximum screening period of 35 days.
  5. Within 6 months prior to screening, there is a documented history indicating an inadequate response or intolerance to topical treatments such as TCS and/or TCI; or a documented history indicating the need for systemic therapy (e.g., systemic , conventional , biologics, Janus kinase [JAK] inhibitors, etc.) to control the disease; [Note] Inadequate response is defined as failure to achieve disease remission or maintain a low disease activity state despite using mid-potency or potent TCS for at least 4 weeks or superpotent TCS for at least 2 weeks as prescribed, or using TCI for at least 4 weeks. Intolerance is defined as worsening of skin lesions after 1-2 weeks of topical treatment, or the occurrence of discomfort including pain, burning, or uncomfortable sensations following drug use.
  6. The subject is able and willing to regularly use a mild, additive-free emollient at least twice daily for at least 7 consecutive days prior to randomization and to continue its use throughout the study period.
  7. The subject (including their partner) agrees to have no pregnancy plans from the time of signing the ICF until 3 months after the last dose and voluntarily adopts effective measures ;

    • Male subjects: Must agree not to donate sperm during the study and for 3 months after the last study drug administration.
    • Female subjects:

      • Women of : Must have a negative serum human chorionic gonadotropin (HCG) test during the screening period and must not be breastfeeding.
      • Women without childbearing potential: Permanently sterilized (e.g., bilateral oophorectomy, bilateral salpingectomy, hysterectomy) or (defined as cessation of menstruation for at least 12 months with other pathological causes excluded; for women under 60 years old, serum follicle-stimulating hormone [FSH] level >40 IU/L must be confirmed).

Exclusion criteria

Exclusion Criteria:

Have used any of the following drugs/treatments within the specified time frames:

  1. Previously participated in any clinical trial of QY201 tablets;
  2. Used the following systemic treatments within 12 weeks before baseline (or 5 half-lives, whichever is longer):

    • Small molecule targeted drugs: JAK inhibitors (e.g., Ruxolitinib, Tofacitinib, Baricitinib, Upadacitinib, Abrocitinib), etc.;
    • Macromolecular biologics: such as Dupilumab, etc.;
  3. Used the following systemic treatments within 4 weeks before baseline (or 5 half-lives, whichever is longer):

    • Systemic /immunomodulatory drugs (e.g., systemic , cyclosporine, mycophenolate mofetil, interferon gamma, azathioprine, methotrexate, etc.);
    • Phototherapy (e.g., ultraviolet B [UVB], psoralen + ultraviolet A [PUVA], etc.), including indoor tanning;
    • Systemic traditional Chinese herbal medicines or proprietary Chinese medicines that may affect efficacy evaluation;
    • Other systemic drugs for treating AD;
  4. Used topical JAK inhibitors for local treatment within 4 weeks before baseline; used the following local treatments within 1 week before baseline:

    • TCS;
    • TCI;
    • Topical phosphodiesterase-4 (PDE-4) inhibitors;
    • Topical traditional Chinese medicine preparations or local herbal baths that may affect efficacy evaluation;
    • Other local drugs for treating AD;
  5. Received allergen-specific immunotherapy within 6 months before baseline;
  6. Used strong inhibitors or inducers of cytochrome P450 3A enzyme () within 2 weeks before baseline (see Appendix 9);
  7. Used long-acting anticoagulants (e.g., warfarin, clopidogrel, etc.) within 4 weeks before baseline or required continuous use of anticoagulant therapy (except aspirin ≤100 mg/day);
  8. Planned to receive or live attenuated vaccines within 4 weeks before baseline; or expected to require live vaccines or live attenuated vaccines during the study period (including at least 4 weeks after the last dose of the product);
  9. Participated in and used any investigational drug within 4 weeks (or 5 half-lives, whichever is longer) before baseline, or participated in and used any medical device in a clinical trial within 3 months;

    Have any of the following medical histories or abnormalities:

  10. Other skin comorbidities that, in the investigator's assessment, may interfere with the study evaluation, aside from AD;
  11. History of disseminated herpes zoster (a single episode) or disseminated herpes simplex (a single episode), or recurrent (≥2 episodes) localized herpes zoster;
  12. Diagnosed or suspected active tuberculosis, latent untreated tuberculosis, or incompletely cured tuberculosis, as judged by the investigator and/or specialist (based on epidemiological history, symptoms, signs, laboratory tests, interferon-gamma release assay, imaging, etc.); unless there is documented evidence of adequate treatment or prophylactic anti-tuberculosis therapy started at least 2 weeks before the investigational product administration (and required to be used until the full course is completed), and the investigator and/or specialist judges that the subject can currently start JAK inhibitor treatment;
  13. Chronic active infection or acute infection requiring systemic treatment with antibiotics, antiviral drugs, antiparasitic drugs, antiprotozoal drugs, or antifungal drugs within 4 weeks before screening; or superficial skin infection requiring treatment within 1 week before screening;
  14. Known history of invasive infections (histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) (even if the infection has been resolved), or, in the investigator's judgment, abnormally frequent, recurrent, or prolonged infections suggesting possible immunodeficiency, or history of (HIV) infection;
  15. Subjects with a history of thromboembolism (including deep vein thrombosis, pulmonary embolism, arterial thrombosis, etc.), or other high-risk populations prone to thromboembolism (the investigator comprehensively judges that such subjects are unsuitable for participation in this study based on clinical assessment);
  16. Any of the following cardiovascular and cerebrovascular diseases/abnormalities:

    • Moderate to severe heart failure ( Class III or IV);
    • Previous large-area cerebral infarction/cerebral hemorrhage, myocardial infarction, coronary artery stent implantation;
    • Poorly controlled or hypertension (after drug control, systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);
    • Significant abnormalities on (ECG), which, in the investigator's judgment, may pose an unacceptable risk to the subject participating in the clinical study, including but not limited to severe arrhythmia, corrected for heart rate using Fridericia's formula (QTcF) >480 ms;
    • Other cardiovascular and cerebrovascular-related medical histories/abnormalities that, in the investigator's judgment, make the subject unsuitable for participation in this study.
  17. Subjects who have undergone or plan to undergo organ transplant surgery and require immunosuppressants (e.g., liver or kidney transplantation);
  18. History of gastrointestinal perforation (except appendicitis or penetrating injury) or diverticulitis;
  19. Conditions that may interfere with drug absorption, including but not limited to short bowel syndrome, gastrectomy, or specific types of bariatric surgery (e.g., gastric bypass surgery);
  20. History of any , except successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix;
  21. History of drug or alcohol abuse within 6 months before screening;
  22. Other cardiovascular diseases, respiratory diseases, digestive diseases, endocrine diseases, diseases, hematological diseases, urinary diseases, neuropsychiatric diseases, etc., that the investigator deems unsuitable for participation in this study;
  23. Subjects who have undergone major surgery within 8 weeks before baseline or plan to undergo major surgery during the study period;
  24. Blood loss ≥400 mL (including trauma, blood sampling, blood donation) within 12 weeks before baseline, or plan to donate blood during the study period or within 1 month after the study ends;
  25. Inability to take oral tablets or allergy to the active ingredient or of the investigational product;

    Have any of the following laboratory abnormalities:

  26. Laboratory abnormalities during screening and at baseline:

    • Blood routine: white blood cells \<2.5×10⁹/L, neutrophils \<1.5×10⁹/L, lymphocyte count \<0.8×10⁹/L; count \<100×10⁹/L, \<100 g/L;
    • Renal function: estimated (eGFR) \<40 mL/min/1.73m², calculated using the Modification of Diet in Renal Disease (MDRD) formula;
    • Liver function: (ALT) or aspartate aminotransferase (AST) >2.0× (ULN) or total (TBIL) >1.5×ULN;
    • Coagulation function: (PT) or activated partial thromboplastin time (APTT) >1.5×ULN;
  27. Abnormalities during screening:

    • surface antigen (HBsAg) positive; or hepatitis B core antibody (HBcAb) positive and hepatitis B virus deoxyribonucleic acid (HBV-DNA) positive;
    • virus (HCV) antibody positive and hepatitis C virus ribonucleic acid (HCV-RNA) positive;
    • Human immunodeficiency virus (HIV) antibody positive;
    • Treponema pallidum antibody positive (except subjects with negative non-treponemal test results and judged by the investigator to have had past syphilis infection that has been cured); [Note] If a subject has abnormal laboratory test results during screening, the investigator may arrange one retest on a different day within the 35-day screening period (no drug intervention for the abnormal laboratory results is allowed before retesting), and the retest results will be used as the basis for determining the subject's eligibility.

    Other:

  28. Any subject whom the investigator considers unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
460 participants (estimated)

Study arms

  • Placebo comparator
    QY201 placebo tablet

    Using QY201placebo tablet twice daily for 16 weeks

    Drug: 10mg QY201 Placebo tablet · Drug: 20mg QY201 Placebo tablet

  • Experimental
    20mg QY201 tablet

    Using 20mg QY201 tablet twice daily for 52 weeks

    Drug: 10mg QY201 Placebo tablet · Drug: 20mg QY201 tablet

  • Experimental
    10mg QY201 tablet

    Using 10mg QY201 tablet twice daily for 52 weeks

    Drug: 20mg QY201 Placebo tablet · Drug: 10mg QY201 tablet

Interventions

  • Drug10mg QY201 Placebo tablet

    10mg QY201 Placebo tablet

  • Drug20mg QY201 Placebo tablet

    20mg QY201 Placebo tablet

  • Drug10mg QY201 tablet

    10mg QY201 tablet

  • Drug20mg QY201 tablet

    20mg QY201 tablet

06

What researchers measure

Primary outcomes

  1. The proportion of subjects who achieved EASI-75 at week 16 of treatment.

    Time frame: At week 16 of treatment

  2. The proportion of subjects who achieved vIGA-AD 0/1 with a reduction of ≥2 points from baseline at week 16 of treatment.

    Time frame: At week 16 of treatment

07

Study locations

1 site
  • EnitiateBioPharma
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2027, 26 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 26 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 18, 2025
StartActual
Mar 12, 2025
Primary completionEst.
May 18, 2027
CompletionEst.
Jul 19, 2027
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07180511
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Mar 12, 2025
Primary completion
May 18, 2027 (estimated)
Completion
Jul 19, 2027 (estimated)
Last update
Sep 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion